Data supporting anti-CD47 as an active therapy combined with the potential of small-molecule therapies to modify macrophage polarity supported development of a platform that would identify combination therapies that could increase (or decrease) the activity of anti-CD47 in NSCLC. The gene discussed is CD47; the disease is non-small cell lung carcinoma.